Drug intelligence / Profile preview

Ruxin Pian

Development stage: Unknown
Lead developer: Qingdao Huanuo Pharmaceutical Biotechnology
Administration: Oral

Overview

Ruxin Pian is a traditional Chinese medicine (TCM) tablet developed by Qingdao Huanuo Pharmaceutical Biotechnology for the treatment of postpartum lactation insufficiency. It is specifically indicated for patients classified under the TCM syndrome of qi and blood deficiency. The medication is intended to stimulate and increase breast milk production in nursing mothers. Ruxin Pian has been evaluated in a randomized, double-blind, parallel-group Phase 2 clinical trial in China (CTR20131897), where its efficacy and safety were compared against Cuiru granules.

Brand names: Ruxin Pian

Beyond the preview

Go deeper on Ruxin Pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ruxin Pian.

Explore the full profile